Press Releases Fortress Biotech, Inc.

Equities

FBIO

US34960Q3074

Real-time Estimate Cboe BZX Other stock markets 03:10:52 2024-05-06 pm EDT			5-day change	1st Jan Change
1.785 ^USD	+2.00%		+3.49%	-40.86%

Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ
Apr. 02	Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer	May. 01	AQ
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	Apr. 29	AQ
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024	Apr. 25	AQ
Avenue Therapeutics Announces Reverse Stock Split	Apr. 24	AQ
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights	Mar. 28	AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	Mar. 26	AQ
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	Mar. 21	AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	Mar. 18	AQ
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	Mar. 15	AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	Mar. 13	AQ
Fortress Biotech to Participate in 36th Annual ROTH Conference	Mar. 12	AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	Mar. 11	AQ
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease	Mar. 04	AQ
Lindsay RosenwaldÃ¢€™s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries	Feb. 02	AQ
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea	Jan. 05	AQ
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Jan. 03	AQ
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy	Jan. 03	AQ
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million	Jan. 02	AQ
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Dec. 29	AQ
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics	Dec. 07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Fortress Biotech, Inc.

Equities

FBIO

US34960Q3074

Press Releases

Filters